Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: Pharmacological targeting PTK6 inhibits the JAK2/STAT3 sustained stemness and reverses chemoresistance of colorectal cancer

Fig. 2

PTK6 promotes the proliferation and chemoresistance of CRC cells. A-B Real-time q-PCR and Western blot assays were performed to verify the successful construction of PTK6 overexpression and knockdown CRC cells. C Colony formation assays were performed to determine the effects of PTK6 on the growth of CRC cells. The number of colonies (> 50 cells) was scored (mean ± SD, n = 3). D CCK-8 assays were performed to determine the effects of PTK6 on the proliferation of CRC cells (mean ± SD, n = 3). (E) Flow cytometry analyses demonstrate the effect of PTK6 on the cell cycle progression (mean ± SD, n = 3). F Flow cytometry analyses show the effects of PTK6 on CRC cell apoptosis after treatment of 5-FU (100 µM) for 12 h(mean ± SD, n = 3). G Cell viability analyses were performed in PTK6 overexpression or silencing CRC cells after 5-FU and L-OHP treatment (mean ± SD, n = 3). H The subcutaneous tumors formed by control and PTK6 silencing HCT116 cells were obtained from nude mice. Both the volume and weight of subcutaneous tumors were shown in the right panel(mean ± SD, n = 3). (I) H&E and IHC staining were used to detect the expression of PTK6 and Ki67 in indicated subcutaneous tumors of nude mice. Scale bar represents 50 μm. *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page